The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Novel prophylactic therapies available before and after transplantation to reduce the risk of GvHD
Featured:
Ali BazarbachiThe GvHD Hub are proud to present expert interviews directly from the 61st American Society of Hematology (ASH) meeting in Orlando, US. This interview with Ali Bazarbachi, American University of Beirut, Beirut, LB, was on the topic of novel prophylactic therapies available before and after transplantation to reduce the risk of graft-versus-host disease.
Ali Bazarbachi discusses the evolving treatment landscape of GvHD prophylaxis and treatment. He explains the success of post-transplant cyclophosphamide in the haploidentical setting. He also discusses the results of a study that examined the use of post-transplant cyclophosphamide in the match related/unrelated setting. Ali Bazarbachi concludes by summarizing the results of a study from the Acute Leukaemia Working Party (ALWP) EBMT, that examined the efficacy of anti-thymocyte globulin or post cyclophosphamide to reduce chronic GvHD.
Novel prophylactic therapies available before and after transplantation to reduce the risk of GvHD